Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV HTL0009936 in healthy elderly and elderly with below-average cognitive function
NL-OMON42111Active, not recruiting
- Sponsor
- Heptares Therapeutics
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of HTL0009936 in Alzheimer's disease (AD) and Dementia (4 arms), sponsored by Heptares Therapeutics. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Concomitant medication use and 15 more. Started Dec 2014; status: active, not recruiting.
02
Drugs
HTL0009936
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on NL-OMON42111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42111.